BioResearcher · Deep Research

BRCA1 DNA Repair: Recent Article Landscape (2023–2026)

Topicbrca1_dna_repair_landscape
Generated2026-09-11
Research Scopelight-research survey of recent literature on BRCA1's DNA repair roles — molecular mechanism and therapeutic exploitation of BRCA1 deficiency.

Executive Summary

Recent literature reframes BRCA1 as an anticipatory genome-maintenance hub whose BRCT-phosphopeptide axis, RAP80/Abraxas damage-site targeting (now understood through liquid-liquid phase separation and K63-ubiquitin chain handling), and replication fork protection duties extend well beyond canonical double-strand break repair [1-4]. In parallel, the clinical literature consolidates around a mechanistically classified map of PARP inhibitor resistance in BRCA1-deficient tumors — reversion mutations, shieldin/53BP1-loss HR restoration, restored gap suppression, RAD51 hyperactivation — matched to next-generation DDR combinations such as ATR inhibition and PROTAC-PARP1 degraders [5-7].

Key findings: - BRCA1's BRCT domain recruits BRCA1-BARD1 to R-loop-bound senataxin (SETX pSer642), preventing transcription-replication conflicts and fork stalling [1]. - RAP80 liquid-liquid phase separation at DSBs — enhanced by K63-polyubiquitin — is required for BRCA1 foci formation [2]; two 2026 studies resolve BRCA1-A's ubiquitin chain-feeding and K63-chain recognition/cleavage mechanisms [3, 4]. - BRCA1's fork duties now include daughter-strand gap repair behind forks (jointly with BRCA2) [8] and a coiled-coil-dependent fork-restart pathway distinct from DSB resection control [9]. - Reversion mutations remain the prototypical acquired PARPi resistance mechanism [10], while ovarian tumors with HRR homozygous loss — immune to reversion — show the most durable PARPi benefit (maintenance PFS HR 0.06; monotherapy median PFS 25.4 vs 4.9 months without HRR alteration) [11]. - Functional HR assays are maturing (BRCA1-foci + RAD51-foci scoring, phospho-RPA2) and being prospectively tested with resistance biomarkers [12-14], while ATR-inhibitor combinations overcome acquired olaparib resistance in BRCA1-mutant models [7].

Data Sources

Source Type Query / accession Date accessed
PubMed / EuropePMC / Semantic Scholar (via biomcp article_search) Literature 11 article_search queries, dateRange "2023-01-01/", limit 8–10 (see Analysis Methodology) 2026-09-11
ClinicalTrials.gov (via biomcp trial_search) Trial registry trial_search(query="BRCA1 PARP inhibitor resistant", status="RECRUITING") 2026-09-11
biomcp article_get Enrichment article_get(id="41917467") core metadata 2026-09-11

Scope: 34 unique evidence records (32 articles + 2 trials) across two aspect ledgers; 13 biomcp tool calls total (7 + 6), within the user-imposed cap of ≤10 per aspect worker. Records: research articles and reviews, 2023–2026, English.

Quality notes: federated recency-filtered search skews BRCA1+HR terms toward clinical venues, narrowing primary-mechanism yield for the HR core (noted per aspect); one admitted source is a bioRxiv preprint [9]; four records were captured but not cited (redundant) — PMIDs 41772736, 42283711, 42465024, 41900841.

Analysis Methodology

Mode: no-interview light-research, two aspects researched in parallel by generic subagent workers (Tier B), each bound to ≤10 biomcp tool calls and sequential-only MCP calls.

  • Aspect hr_mechanisms — 7 calls: 6× article_search (query families: "HR RAD51 PALB2 recruitment", "replication fork protection fork reversal", "PALB2 BRCA2 RAD51 cryo-EM structure mechanism", "RAP80 Abraxas ubiquitin recruitment", "phase separation condensates DSB repair", "BARD1 RAD51 loading D-loop"; all dateRange "2023-01-01/", limit 10) + 1× article_get (PMID 41917467).
  • Aspect parpi_resistance_clinical — 6 calls: 5× article_search ("PARP inhibitor resistance reversion mutation", "replication fork protection shieldin 53BP1", "functional HR assay RAD51 foci HRD predicts response", "drug-tolerant persister BRCA1 adaptation" + retry) + 1× trial_search (status RECRUITING).
  • Evidence discipline: workers applied binding inclusion/exclusion criteria (criterion vs keyword), excluded keyword-matching off-topic candidates explicitly, and keyed every quantitative claim to its ledger record at capture time. Orchestrator ran the per-aspect completion gate (evidence-ledger check: 64 markers resolved, 0 problems), merged ledgers, verified against NCBI esummary, rendered numbered citations, and re-audited with vet-references.

Findings

1. Mechanistic core: BRCT axis and damage-site targeting (confidence: High)

  • The BRCA1-BARD1 heterodimer binds R-loops and stimulates their unwinding by senataxin (SETX); phosphorylation of SETX at Ser642 creates the binding site for BRCA1's tandem BRCT domain, and BRCA1-BARD1 additionally counteracts RAD52 inhibition of SETX. SETX catalytic or Ser642 mutants accumulate R-loops, transcription-replication conflicts, fork stalling, and DSBs [1]. This extends BRCT-phosphopeptide recognition into genome-maintenance interactions beyond canonical DSB factors.
  • Chromatin state primes recruitment: CTCF-primed repressive chromatin supports rapid BRCA1/BARD1 recruitment for HR repair of DSBs [15].
  • RAP80 undergoes liquid-liquid phase separation at DSBs via its N-terminal intrinsically disordered region, enhanced by damage-induced K63-linked polyubiquitin; loss of condensation suppresses BRCA1 foci and alters radiosensitivity [2]. Two 2026 studies resolve how the BRCA1-A complex feeds K63-ubiquitin chains to BRCC36 [3] and recognizes/cleaves K63-linked polyubiquitin [4]; functionally, BRCA1-A restricts fork-reversal-dependent repair in ATM-deficient cells [16].
  • Context reviews situate BRCA1's RING E3 ligase within E3-ligase wiring of replication-coupled repair [17] and ubiquitin/SUMO pathway control of replication-associated repair [18], alongside single-molecule biochemical reconstitution of the HR machinery [19]; no dedicated 2023+ primary RING-substrate study surfaced (see Limitations).

2. Replication fork protection, restart, and gap repair (confidence: High)

  • Fork-destabilizing consequences of BRCA1 loss are mechanistically resolved: USP37 (a whole-genome CRISPR-screen determinant of PARPi toxicity in BRCA1-deficient cells) deubiquitinates RPA at stalled forks to prevent RPA exhaustion and ssDNA-to-DSB conversion, and limits HLTF-driven MRE11-dependent fork degradation; its ablation enhances PARPi sensitivity and overcomes 53BP1-loss resistance [20]. In BRCA1-deficient TNBC models, gemcitabine exposes unprotected nascent DNA at reversed forks, triggering MRE11 over-resection, ssDNA accumulation without RPA/RAD51 foci, mitotic bridges, micronuclei, and mitotic catastrophe — an effect not shared by olaparib [21].
  • Compensatory routes exist: IFI16 binds nascent DNA at stalled forks, protecting remodeled fork ends (protected redundantly by BRCA1 and BRCA2) from MRE11/EXO1/DNA2, and is required for interferon-mediated rescue of fork protection in BRCA-deficient cells [22].
  • BRCA1's fork duties extend to restart and gap repair: a preprint maps a coiled-coil-dependent BRCA1 activity driving stalled-fork restoration via RAD51 regulation with SCAI/REV3 dependency (and SLX4-mediated break formation in their absence), regulated independently of DSB resection control [9]. A 2026 primary study shows wild-type cells repair olaparib-induced nascent-strand gaps (unligated Okazaki fragments) through daughter-strand gap protection/repair hundreds of kilobases behind forks, jointly dependent on BRCA1 and BRCA2, with BRCA2-dependent RAD51 chromatin loading — independent of fork reversal and PRIMPOL repriming [8].

3. BRCA1 vs BRCA2 division of labor (confidence: Medium)

  • A 2026 review reframes RAD51 with BRCA1/BRCA2 as a "prevent and protect" anticipatory genome-maintenance network — shielding DNA from MRE11 processing, promoting fork reversal, suppressing replicative gaps, binding abasic sites — whose failure yields distinctive mutational signatures through rewired BER/TLS interfaces [23].
  • Experimentally separated duties: RAD51 chromatin loading in gap repair is BRCA2-dependent while requiring BRCA1 jointly [8]; remodeled fork ends are protected redundantly by both [22]; BRCA1's fork-restart control (SCAI/REV3/SLX4, RIF1-modulated) is domain-separable from its resection control [9].

4. PARPi resistance mechanisms in BRCA1-deficient tumors (confidence: High)

  • Reversion mutations — secondary intragenic BRCA1/2 mutations restoring the reading frame — remain the prototypical acquired resistance mechanism across BRCA1/2-mutated breast, ovarian, pancreatic, and prostate cancers [10]. The mirror image: among 5,404 advanced ovarian cancers, the 1.5% (82) with HRR homozygous loss (most BRCA1 losses intragenic; 89% of BRCA1 losses, 34/38) showed the most durable PARPi benefit — maintenance PFS HR 0.06 (95% CI 0.01–0.37) and monotherapy median PFS 25.4 months vs 4.9 months without HRR alteration (median OS 51.8 vs 18.5 months) [11].
  • Resistance is now formally classified into mechanistically distinct categories — BRCA1/2 reversion, 53BP1/shieldin-mediated HR restoration (with a collateral DNA ligase III dependence), replication fork stabilization, Polθ-mediated TMEJ, ABCB1 efflux, and cGAS–STING-mediated immune evasion [5].
  • Mechanistic framing is shifting from DSBs toward ssDNA gaps: restoration of replication-gap suppression and transcription-replication-conflict tolerance is positioned as a central resistance route [6], organized hierarchically from pathway restoration to replication-stress tolerance states [24]. RAD51 hyperactivation is repeatedly listed among established resistance mechanisms [6, 25].
  • BRCA1 status alone does not fix response: GSK3β-directed chromosomal repair-pathway choice supports BRCA1-independent PARPi sensitivity [26].

5. Functional HR assays and biomarkers (confidence: Medium-High)

  • Genomic scar-based HRD tests dominate clinically; a 2025 technical-validation review maps the HRD testing landscape and its diagnostic applications [27].
  • Protein-based functional readouts are advancing: low BRCA1-foci score predicted olaparib/cisplatin response in an ovarian PDX platform, improved by combination with RAD51-foci scoring [12]; phospho-RPA2 predicts platinum/PARPi response even in HR-proficient ovarian cancers [13].
  • Integrated proposals combine scar assays, RAD51 foci, gap profiling, and ctDNA monitoring for real-time resistance tracking [5, 6]; POLQ/shieldin/53BP1 resistance biomarkers are being tested prospectively in germline BRCA1/2-mutated HER2-negative metastatic breast cancer [14].

6. Combination strategies and trial landscape (confidence: Medium-High)

  • ATR inhibition overcame acquired olaparib resistance in BRCA1-mutant TNBC models (HCC1937/MDA-MB-436): ATR+PARP synergy, suppressed xenograft growth, and downregulation of BRCA2/RAD51 reversing HR-repair signaling [7]; ATR combinations show promising activity in PARPi-resistant HR-deficient ovarian cancer [6].
  • The TNBC next-generation DDR target landscape spans ATR/CHK1, WEE1, DNA-PK, RAD51, POLQ, neddylation, and targeted degradation (including PROTAC-PARP1 degraders), with PARPi/platinum as the validated backbone [6, 28].
  • Trials: a phase II niraparib study in advanced pancreatic cancer with ATM/BRCA1/BRCA2/PALB2/CHEK2 pathogenic variants extends PARPi monotherapy evidence including BRCA1-mutant disease [29]; recruiting studies address BRCA1-deficient resistance directly — olaparib + ceralasertib or cediranib in germline BRCA-mutated metastatic breast cancer [30] and the resistance-biomarker study above [14]. Pan-cancer syntheses consolidate 2024–2026 trial support (PETRA, EvoPAR-Prostate01/02, STELLA, MEDIOLA, TOPACIO, ATHENA-COMBO, CAPRI, DUO-O) for resistance-class-matched strategies [5].

Limitations

  • Data gaps: no dedicated 2023+ primary study of BRCA1 RING-domain E3 substrate specificity surfaced (coverage rests on reviews [17, 18]); no intact BRCA1-PALB2-BRCA2-RAD51 cryo-EM structure was retrieved; canonical mitotic BRCT-ligand interactions (Abraxas/CtIP phospho-epitopes) did not surface as dedicated 2023+ studies; no BRCA1-specific drug-tolerant-persister study was found after original + simpler retry — the theme is covered only indirectly [6, 24].
  • Source coverage: recency-filtered federated search skews BRCA1+HR terms toward clinical/translational venues (the aspect-1 HR-core query returned exclusively clinical results); the RECRUITING-only trial filter returned 2 studies, so completed phase III readouts are covered second-hand through syntheses [5]; niraparib pancreatic trial outcome metrics were absent from retrieved metadata and are not asserted [29].
  • Evidence caveats: one admitted source is a bioRxiv preprint (not yet peer-reviewed at retrieval) [9]; PALB2-BRCA2-RAD51 recruitment arm coverage is review-level [19]; no auth-gated tools were needed (OncoKB/DisGeNET not used).
  • Methodological constraints: light-research mode (2 aspects, ≤10 biomcp calls per worker) trades depth for speed; quantitative claims are keyed to their ledger records but were not independently re-computed; the 2023+ window omits pre-2023 foundational work.
  • Generalizability: findings emphasize breast/ovarian archetypes; BRCA1-deficient prostate/pancreatic coverage is thinner.

References

[1] Dutta A, Ji J, Syed S, et al. Resolution of R-loops and transcription-replication conflicts by SETX-BRCA1-BARD1 complex. Nat Struct Mol Biol. 2026;33(4):615-630. DOI: 10.1038/s41594-026-01778-8. PMID: 41917467. [2] Qin C, Wang Y, Zhou J, et al. RAP80 phase separation at DNA double-strand break promotes BRCA1 recruitment. Nucleic Acids Res. 2023;51(18):9733-9747. DOI: 10.1093/nar/gkad686. PMID: 37638744. [3] Murachelli AG, El OF, Sixma TK. A ubiquitin chain-feeding mechanism for BRCA1-A. Nat Commun. 2026;17(1). DOI: 10.1038/s41467-026-75797-w. PMID: 42581048. [4] Foglizzo M, Datta A, Degtjarik O, et al. Mechanism of K63-linked polyubiquitin recognition and cleavage by the BRCA1-A complex. Nat Commun. 2026;17(1). DOI: 10.1038/s41467-026-75795-y. PMID: 42581301. [5] Qin S, An J, Qiao W, et al. Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors. Biomed Pharmacother. 2026;201:119670. DOI: 10.1016/j.biopha.2026.119670. PMID: 42314345. [6] Abinawanto, Sophian A. Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription-Replication Conflicts to PROTAC-Based Next-Generation Strategies. Environ Mol Mutagen. 2026;67(5-7):e70076. DOI: 10.1002/em.70076. PMID: 42590926. [7] Huang L, Yang Y, Dai L, et al. AZD6738 overcomes acquired olaparib resistance in BRCA1 mutation triple-negative breast cancer through down-regulation of BRCA2 and RAD51. Sci Rep. 2026;16(1). DOI: 10.1038/s41598-026-52778-z. PMID: 42120731. [8] Milano L, Wells S, Vaitsiankova A, et al. BRCA2-dependent maturation of nascent strands during DNA replication. Mol Cell. 2026;86(8):1427-1440.e5. DOI: 10.1016/j.molcel.2026.03.012. PMID: 41935526. [9] Unterseher C, Tsuchida H, Bosire R, et al. The BRCA1- RAD51 Axis Regulates SCAI/REV3 Dependent Replication Fork Maintenance. bioRxiv. 2025. DOI: 10.1101/2025.11.25.689574. PMID: 41394680. [10] Qi W, Yang G, Zhang Y, et al. BRCA1/2 Reversion Mutations and Cancer Therapy Resistance. Biology (Basel). 2026;15(11). DOI: 10.3390/biology15110866. PMID: 42274517. [11] Swisher EM, Konecny G, Cohen J, et al. Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer. JCO Precis Oncol. 2026;10(5):e2500763. DOI: 10.1200/po-25-00763. PMID: 42133897. [12] Guffanti F, Mengoli I, Alvisi MF, et al. BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models. Front Pharmacol. 2024;15:1390116. DOI: 10.3389/fphar.2024.1390116. PMID: 38989145. [13] Schab A, Compadre A, Drexler R, et al. Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. J Clin Invest. 2025;135(13). DOI: 10.1172/jci189511. PMID: 40392598. [14] NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. Status: RECRUITING. https://clinicaltrials.gov/study/NCT05378204 [15] Hwang SY, Choi D, Choi MJ, et al. CTCF primes repressive chromatin for rapid BRCA1/BARD1 recruitment to drive homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res. 2026;54(14). DOI: 10.1093/nar/gkag715. PMID: 42475683. [16] Datta A, Jackson J, Morozov YI, et al. The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells. Nat Commun. 2026;17(1). DOI: 10.1038/s41467-026-75271-7. PMID: 42401588. [17] Chauhan AS, Jhujh SS, Stewart GS. E3 ligases: a ubiquitous link between DNA repair, DNA replication and human disease. Biochem J. 2024;481(14):923-944. DOI: 10.1042/bcj20240124. PMID: 38985307. [18] Fiedorowicz LM, Baxley RM, Hendrickson EA, et al. Ubiquitin and SUMO pathways in DNA replication and replication-coupled repair. Crit Rev Biochem Mol Biol. 2025;60(4-6):287-314. DOI: 10.1080/10409238.2025.2574638. PMID: 41134662. [19] Raina VB, Jessop A, Greene EC. Biochemical Mechanisms of Genetic Recombination and DNA Repair. Annu Rev Biochem. 2025;94(1):161-193. DOI: 10.1146/annurev-biochem-083024-113931. PMID: 40153609. [20] Tang M, Li S, Zhu Z, et al. USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance. Nucleic Acids Res. 2025;53(12). DOI: 10.1093/nar/gkaf544. PMID: 40548939. [21] Tabet I, Orhan E, Candiello E, et al. Replication-Poison Treatment in BRCA1-Deficient Breast Cancer Causes MRE11 Over-Resection That Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe. Cancer Res. 2025;85(8):1410-1423. DOI: 10.1158/0008-5472.can-24-1404. PMID: 39879120. [22] Gamble A, Ward TA, Wheeler OPG, et al. IFI16 senses and protects stalled replication forks. Mol Cell. 2026;86(2):258-272.e6. DOI: 10.1016/j.molcel.2025.12.024. PMID: 41512859. [23] Sassi L, Martinez MA, Waked S, et al. The expanding roles of homologous recombination proteins in genome stability. EMBO J. 2026;45(3):637-654. DOI: 10.1038/s44318-025-00673-0. PMID: 41484372. [24] Morgera V, Feola A, Romano A, et al. Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance. Exp Hematol Oncol. 2026;15(1). DOI: 10.1186/s40164-026-00779-z. PMID: 42116135. [25] Anjum RS, Takabe K. RAD51 in Breast Cancer: From Vulnerability to Resistance. World J Oncol. 2026;17(4):429-441. DOI: 10.14740/wjon2764. PMID: 42490812. [26] Leung JW, Gius D. GSK3beta guides chromosomal repair pathway selection to support BRCA1-independent PARP inhibitor sensitivity. J Clin Invest. 2025;135(22). DOI: 10.1172/jci197910. PMID: 41243967. [27] Witz A, Dardare J, Betz M, et al. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. Biomark Res. 2025;13(1):31. DOI: 10.1186/s40364-025-00740-y. PMID: 39985088. [28] Jonczyk J, Czopek A, Kvinta U, et al. Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality. Molecules. 2026;31(13). DOI: 10.3390/molecules31132303. PMID: 42451670. [29] Huffman BM, Diossy M, Yurgelun MB, et al. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Clin Cancer Res. 2026;32(9):1666-1677. DOI: 10.1158/1078-0432.ccr-24-3766. PMID: 41686836. [30] NCT04090567: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer. Status: RECRUITING. https://clinicaltrials.gov/study/NCT04090567

Table of Contents